GDF-Medical Products Support and Advanced Concept Development
Abstract
Guidance for Development of the Force (GDF)-Medical Products Support and Advanced Concept Development: This funding supports (1) clinical trials of promising technologies that may provide solutions for the most pressing medical needs of the Warfighter, (2) accelerated transition of promising technologies to the field, and (3) promulgation of new, evidence-based approaches to the practice of medicine as clinical practice guidelines. Research will be conducted in the following areas: (1) Medical Simulation and Information Sciences/JPC-1. This JPC seeks to promote long-term efficiencies by defining processes improving the electronic healthcare record/other medical related systems, and the implementation of new trends and advancements in technology to improve healthcare access, availability, continuity, cost effectiveness, and quality. Initial candidates will be selected from those funded by other medical research sponsors in the Department, and from external sources such as academia and industry, including efforts funded with prior year CSI funding; (2) Military Infectious Disease/JPC-2. This JPC supports the advanced development of systems to rapidly detect pathogens (infectious agents)in fresh whole blood, as well as efforts related to the prevention and management of wound infections and the development of antimicrobial countermeasures and infectious disease-related diagnostic systems; (3) Military Operational Medicine/JPC-5. This JPC supports clinical assessments related to interventions for post-traumatic stress disorder (PTSD), nutrition and dietary supplementation to promote health and resilience, the development of mitigation strategies to prevent hearing loss, the development of techniques to enhance military family and community health and resilience, validation trials for enhanced suicide prevention, and the accomplishment of related field studies with end users; (4) Combat Casualty Care/JPC-6. This JPC supports clinical trials such as those assessing biomarkers (biological indicators) for traumatic brain injury (TBI) and spinal cord injury, product development related to forward surgical/intensive critical care, enroute care, hemorrhage and resuscitation, and treatments for tissue injury; (5) Clinical and Rehabilitative Medicine/JPC-8. Advanced development efforts in this JPC involve clinical trials related to pain management and regenerative medicine.
Document Details
- Document Type
- Project
- Publication Date
- Oct 01, 2016
- Source ID
- 374A_0604110HP_2_0130_PB_2016